Daré Bioscience (DARE) AI Stock Analysis

• Market Cap: $24.40M
• Dividend Yield: N/A
• Average Volume (3M): 170.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 13,479,502
• 10 Day Avg. Volume: 281,723
• 30 Day Avg. Volume: 170,743
• PEG Ratio: 0.07
• Price to Book (P/B): -4.41
• Price to Sales (P/S): 2709.59
• P/FCF Ratio: 5.50
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: -1.37K
• Enterprise Value/Gross Profit: -1.70
• Enterprise Value/Ebitda: -1.36
• 1Y Price Target: $10.33
• Price Target Upside: 464.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▲(9.29% Upside)

Daré Bioscience's overall stock score is primarily impacted by its financial performance, which indicates significant challenges with unprofitability and financial instability. While the earnings call provided an optimistic outlook with strategic initiatives and upcoming product launches, the technical analysis and valuation suggest caution. The stock's oversold condition may present a potential opportunity if the company's strategic plans materialize successfully.

Positive Factors

Product Pipeline Progress

The continuation of the Ovaprene Phase III trial without safety concerns and potential commercialization by Bayer indicates strong product pipeline progress, enhancing Daré's market position in women's health.

Strategic Partnerships

Partnerships like the one with Bayer for Ovaprene commercialization provide financial backing and market access, crucial for Daré's growth and competitive advantage in the biotechnology sector.

Financial Strengthening

The recent financial inflow from stock sales and grants strengthens Daré's balance sheet, providing necessary capital to support ongoing R&D and potential product launches, crucial for long-term sustainability.

Negative Factors

Financial Instability

Ongoing financial instability, marked by negative equity and unprofitability, poses significant risks to Daré's ability to sustain operations and invest in growth, threatening long-term viability.

Working Capital Deficit

A substantial working capital deficit limits Daré's operational flexibility and ability to invest in strategic initiatives, potentially hindering growth and innovation in the competitive biotech industry.

High Operational Costs

High operational costs leading to negative EBIT and EBITDA margins indicate inefficiencies that could erode profitability and limit Daré's ability to compete effectively in the long term.

Daré Bioscience Business Overview & Revenue Model

Company Description

Daré Bioscience, Inc. is a clinical-stage biotechnology company focused on advancing innovative products for women's health. The company develops therapeutic solutions aimed at addressing unmet medical needs in areas such as contraception, sexual health, and reproductive health. With a portfolio that includes a range of product candidates, Daré aims to improve the quality of life for women through innovative and effective healthcare solutions.

How the Company Makes Money

Daré Bioscience generates revenue primarily through a combination of product development partnerships, grants, and potential future product sales. The company collaborates with various pharmaceutical companies and research institutions to develop its product candidates, which may involve upfront payments, milestone payments, and royalties on future sales. Additionally, Daré may receive funding from government grants or other sources aimed at supporting research and development in women's health. As the company advances its product candidates through clinical trials and regulatory approval processes, it aims to monetize these assets through commercialization agreements or partnerships, thereby creating significant revenue opportunities.

Daré Bioscience Financial Statement Overview

Summary

Daré Bioscience faces significant financial challenges, including persistent unprofitability and negative equity, indicating financial distress. Despite recent positive trends in cash flow and revenue growth, the company's long-term sustainability remains questionable without a turnaround in profitability and a more stable balance sheet.

Income Statement

Daré Bioscience has struggled with profitability, as evidenced by consistently negative net income over the years. While there was a notable increase in revenue in 2024, the gross profit margin remains 100% due to revenue equaling gross profit, but this is overshadowed by significant negative EBIT and EBITDA margins, indicating high operational costs. The revenue growth from 2023 to 2024 is positive, which is a good sign, but the company remains unprofitable overall.

Balance Sheet

The balance sheet reveals a worrying situation with negative stockholders' equity, indicating financial instability. Additionally, the debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged with total liabilities exceeding total assets. The negative equity ratio suggests insolvency risk, which is a significant concern for stakeholders.

Cash Flow

While Daré Bioscience has managed to generate a positive operating cash flow in 2024, indicating some operational efficiency, the free cash flow remains inconsistent over the years. The positive free cash flow to net income ratio in 2024 is a positive indicator, but the historical volatility in cash flows points to potential financial management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-17.70K	9.78K	2.81M	10.00M	0.00	0.00
Gross Profit	-14.25M	-503.54K	2.77M	9.95M	-26.41K	-43.23K
EBITDA	-17.84M	-23.41M	-30.90M	-31.36M	-39.04M	-27.36M
Net Income	-18.60M	-4.05M	-30.16M	-30.95M	-38.33M	-27.40M
Balance Sheet
Total Assets	12.98M	22.10M	21.28M	43.83M	55.81M	7.55M
Cash, Cash Equivalents and Short-Term Investments	5.04M	15.70M	10.48M	34.67M	51.67M	4.67M
Total Debt	3.03M	1.30M	1.40M	488.74K	270.55K	756.84K
Total Liabilities	25.71M	28.11M	26.33M	32.71M	17.05M	8.70M
Stockholders Equity	-12.73M	-6.01M	-5.05M	11.11M	38.75M	-1.15M
Cash Flow
Free Cash Flow	-11.87M	4.82M	-39.49M	-18.15M	-28.78M	-25.25M
Operating Cash Flow	-11.59M	5.39M	-38.86M	-18.09M	-28.76M	-25.23M
Investing Cash Flow	-284.46K	-573.05K	-629.43K	-63.07K	-14.52K	-17.63K
Financing Cash Flow	507.21K	433.83K	15.64M	1.34M	75.85M	25.13M

Daré Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DARE, the sentiment is Negative. The current price of 1.83 is below the 20-day moving average (MA) of 2.00, below the 50-day MA of 2.07, and below the 200-day MA of 2.61, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 34.64 is Neutral, neither overbought nor oversold. The STOCH value of 12.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DARE.

Daré Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DARE	46 Neutral	$24.40M	-4.10	―	―	―	―
PASG	44 Neutral	$20.72M	-0.36	-88.27%	―	―	32.57%
BOLD	40 Underperform	$28.21M	―	-44.88%	―	―	-0.50%
HIND	37 Underperform	$32.77M	―	-101.49%	―	-19.81%	93.32%
NRSN	30 Underperform	$25.59M	-1.78	―	―	―	31.09%

Daré Bioscience Corporate Events

Daré Bioscience Advances Progesterone Delivery Study for Preterm Birth Prevention

Daré Bioscience, in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, is conducting a study titled ‘An Open-Label, Four-Treatment, Parallel Study of the Comparative Pharmacokinetics of a Progesterone Intravaginal Ring (IVR) 8 mg and 12 mg/Day Versus Progesterone Vaginal Insert 100mg.’ The study aims to compare how different progesterone delivery methods affect hormone levels in the body, focusing on potential treatments for preterm birth.

Daré Bioscience’s Ovaprene Study: A New Era in Contraceptive Innovation

Daré Bioscience is currently conducting a pivotal clinical study titled ‘A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene.’ The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene, a non-hormonal intravaginal ring. This research is significant as it explores a novel contraceptive option that could expand choices for women seeking non-hormonal methods.

Daré Bioscience Engages Market with New Presentation

Daré Bioscience, Inc. announced that it will use a corporate presentation dated September 2, 2025, in various meetings with securities market participants. The presentation will be available on the company’s website in the ‘Investors’ section, indicating a strategic move to engage with stakeholders and potentially enhance its market presence.

The most recent analyst rating on (DARE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Daré Bioscience’s Earnings Call: Optimism Amid Challenges

In the recent earnings call, Daré Bioscience expressed an optimistic outlook, highlighting significant progress in their dual-path strategy and upcoming product launches. Despite technical difficulties and a working capital deficit, the company remains focused on future growth, aiming to drive revenue and expand its market presence.

Daré Bioscience Announces Q2 2025 Financial Results

Daré Bioscience is a biopharmaceutical company focused on addressing unmet needs in women’s health through innovative solutions in areas such as contraception, sexual health, and menopause.